Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LY-2584702 tosylate salt is a selective, ATP-competitive p70S6K inhibitor, used in trials studying the treatment of cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 31.00 | |
2 mg | In stock | $ 44.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 122.00 | |
25 mg | In stock | $ 228.00 | |
50 mg | In stock | $ 378.00 | |
100 mg | In stock | $ 538.00 | |
500 mg | In stock | $ 1,150.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 97.00 |
Description | LY-2584702 tosylate salt is a selective, ATP-competitive p70S6K inhibitor, used in trials studying the treatment of cancer. |
Targets&IC50 | p70 S6K:4 nM |
In vitro | In HCT116 colon cancer cells, LY2584702 inhibits phosphorylation of the S6 ribosomal protein (pS6) with IC50 of 0.1-0.24 μM. [1] LY2584702 has significant synergistic effects when combined with EGFR inhibitor erlotinib or with the mTOR inhibitor everolimus. [2] |
In vivo | LY2584702 (12.5 mg/kg BID), demonstrates significant antitumor efficacy in both U87 mg glioblastoma and HCT116 colon carcinoma xenograft models. [1] |
Synonyms | LY2584702 tosylate |
Molecular Weight | 617.62 |
Formula | C28H27F4N7O3S |
CAS No. | 1082949-68-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 7 mg/mL(11.3 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LY-2584702 tosylate salt 1082949-68-5 MAPK PI3K/Akt/mTOR signaling S6 Kinase LY 2584702 inhibit S6K LY2584702 LY 2584702 Tosylate LY-2584702 Inhibitor LY2584702 tosylate LY 2584702 tosylate salt LY2584702 tosylate salt LY2584702 Tosylate LY-2584702 Tosylate Ribosomal S6 Kinase (RSK) inhibitor